4CPS-062 Evaluation and follow-up of paediatric patient with short bowel syndrome on treatment with teduglutide: case report
Background and ImportanceShort bowel syndrome (SBS) is an unusual disorder caused by resection of a part of the small bowel. Frequently these patients are dependent on total parenteral nutrition (TPN) because they suffer malnutrition. Long-term TPN is associated with complications such as infections...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A44-A45 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A45 |
---|---|
container_issue | Suppl 1 |
container_start_page | A44 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 30 |
creator | Gomez Sanchez, MT Fernandez Gines, FD Sanchez Rodriguez, B Gamez Torres, D Sanchez Valera, M Moreno Diaz, T |
description | Background and ImportanceShort bowel syndrome (SBS) is an unusual disorder caused by resection of a part of the small bowel. Frequently these patients are dependent on total parenteral nutrition (TPN) because they suffer malnutrition. Long-term TPN is associated with complications such as infections and thrombosis. Teduglutide is a glucagon-like peptide (GLP-2) analogue that increases the proliferation of intestinal mucosal cells causing an increase in the absorption surface area and a reduction in the volume of TPN.Aim and ObjectivesTo evaluate the effectiveness of teduglutide in a PN-dependent paediatric patient with SBS.Material and MethodsA retrospective, observational and descriptive study of the only referenced case was designed to evaluate the effectiveness of treatment with Teduglutide. For this purpose, the reduction of the volume of TPN until its withdrawal was analysed. This withdrawal must be complete to establish the success of treatment with teduglutide. Data were extracted from the clinical database of the Andalusian Health System (Diraya).ResultsThe patient needed a TPN per day. The following figure shows the percentage of volume of TPN varied every two months from the start of treatment in our patient. The volume of TPN was 500 mL when the first dose of teduglutide (0.05 mg/kg/day) was administered. However, the volume decreased by 45.6% (272mL) after 14 months. Subsequently, volume increases of up to 8% (month 18) were detected due to admissions for diarrheal crises.Finally, PN was suspended due to multiple complications after 22 months.Abstract 4CPS-062 Figure 1Conclusion and RelevanceIn our case, the percentage of TPN volume reduction is higher compared to other studies collected in a recent meta-analysis.1 Moreover, the TPN was totally withdrawn in less time than described in some studies.References and/or Acknowledgements1. Bioletto, F., D’Eusebio, C., Merlo, F.D., Aimasso, U., Ossola, M., Pellegrini, M., Ponzo, V., Chiarotto, A., de Francesco, A., Ghigo, E., Bo, S. Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis. Nutrients 2022, 14, 796. https://doi.org/10.3390/nu14040796Conflict of InterestNo conflict of interest |
doi_str_mv | 10.1136/ejhpharm-2023-eahp.94 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2790201100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2790201100</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1174-78711868cac966bde04d2258e6bf2a8fcedf1b2ba1144bfc425a26be391694f73</originalsourceid><addsrcrecordid>eNpFkM1KxDAUhYMoOIzzCELAdcYkTdPGnQzjDwwoqOuSNDe2Q6epaergRtz4oj6JHcaf1T2L75wLH0KnjM4ZS-Q5rKuu0mFDOOUJAV11cyUO0IRTkRGlpDj8y6k8RrO-rw1NkyRXIlET9C4W9w-ESv718bl81c2gY-1brFuLnW8avyVDh73DnQZb6xjqcoyxhjbibR0r3Fc-RGz8Fhrcv7U2-A3gcSAG0HHzh0Www3MzxNrCBS51DzhANzZP0JHTTQ-znztFT1fLx8UNWd1d3y4uV8QwlgmS5RljucxLXSopjQUqLOdpDtI4rnNXgnXMcKMZE8K4UvBUc2kgUUwq4bJkis72u13wLwP0sVj7IbTjy4JninLKGKUjxfaU2az_AUaLneni13SxM13sTBejw2-aKHep</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2790201100</pqid></control><display><type>article</type><title>4CPS-062 Evaluation and follow-up of paediatric patient with short bowel syndrome on treatment with teduglutide: case report</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Gomez Sanchez, MT ; Fernandez Gines, FD ; Sanchez Rodriguez, B ; Gamez Torres, D ; Sanchez Valera, M ; Moreno Diaz, T</creator><creatorcontrib>Gomez Sanchez, MT ; Fernandez Gines, FD ; Sanchez Rodriguez, B ; Gamez Torres, D ; Sanchez Valera, M ; Moreno Diaz, T</creatorcontrib><description>Background and ImportanceShort bowel syndrome (SBS) is an unusual disorder caused by resection of a part of the small bowel. Frequently these patients are dependent on total parenteral nutrition (TPN) because they suffer malnutrition. Long-term TPN is associated with complications such as infections and thrombosis. Teduglutide is a glucagon-like peptide (GLP-2) analogue that increases the proliferation of intestinal mucosal cells causing an increase in the absorption surface area and a reduction in the volume of TPN.Aim and ObjectivesTo evaluate the effectiveness of teduglutide in a PN-dependent paediatric patient with SBS.Material and MethodsA retrospective, observational and descriptive study of the only referenced case was designed to evaluate the effectiveness of treatment with Teduglutide. For this purpose, the reduction of the volume of TPN until its withdrawal was analysed. This withdrawal must be complete to establish the success of treatment with teduglutide. Data were extracted from the clinical database of the Andalusian Health System (Diraya).ResultsThe patient needed a TPN per day. The following figure shows the percentage of volume of TPN varied every two months from the start of treatment in our patient. The volume of TPN was 500 mL when the first dose of teduglutide (0.05 mg/kg/day) was administered. However, the volume decreased by 45.6% (272mL) after 14 months. Subsequently, volume increases of up to 8% (month 18) were detected due to admissions for diarrheal crises.Finally, PN was suspended due to multiple complications after 22 months.Abstract 4CPS-062 Figure 1Conclusion and RelevanceIn our case, the percentage of TPN volume reduction is higher compared to other studies collected in a recent meta-analysis.1 Moreover, the TPN was totally withdrawn in less time than described in some studies.References and/or Acknowledgements1. Bioletto, F., D’Eusebio, C., Merlo, F.D., Aimasso, U., Ossola, M., Pellegrini, M., Ponzo, V., Chiarotto, A., de Francesco, A., Ghigo, E., Bo, S. Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis. Nutrients 2022, 14, 796. https://doi.org/10.3390/nu14040796Conflict of InterestNo conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2023-eahp.94</identifier><language>eng</language><publisher>London: British Medical Journal Publishing Group</publisher><subject>Case reports ; Conflicts of interest ; Pediatrics ; Section 4: Clinical pharmacy services</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A44-A45</ispartof><rights>European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2023 European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Gomez Sanchez, MT</creatorcontrib><creatorcontrib>Fernandez Gines, FD</creatorcontrib><creatorcontrib>Sanchez Rodriguez, B</creatorcontrib><creatorcontrib>Gamez Torres, D</creatorcontrib><creatorcontrib>Sanchez Valera, M</creatorcontrib><creatorcontrib>Moreno Diaz, T</creatorcontrib><title>4CPS-062 Evaluation and follow-up of paediatric patient with short bowel syndrome on treatment with teduglutide: case report</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><description>Background and ImportanceShort bowel syndrome (SBS) is an unusual disorder caused by resection of a part of the small bowel. Frequently these patients are dependent on total parenteral nutrition (TPN) because they suffer malnutrition. Long-term TPN is associated with complications such as infections and thrombosis. Teduglutide is a glucagon-like peptide (GLP-2) analogue that increases the proliferation of intestinal mucosal cells causing an increase in the absorption surface area and a reduction in the volume of TPN.Aim and ObjectivesTo evaluate the effectiveness of teduglutide in a PN-dependent paediatric patient with SBS.Material and MethodsA retrospective, observational and descriptive study of the only referenced case was designed to evaluate the effectiveness of treatment with Teduglutide. For this purpose, the reduction of the volume of TPN until its withdrawal was analysed. This withdrawal must be complete to establish the success of treatment with teduglutide. Data were extracted from the clinical database of the Andalusian Health System (Diraya).ResultsThe patient needed a TPN per day. The following figure shows the percentage of volume of TPN varied every two months from the start of treatment in our patient. The volume of TPN was 500 mL when the first dose of teduglutide (0.05 mg/kg/day) was administered. However, the volume decreased by 45.6% (272mL) after 14 months. Subsequently, volume increases of up to 8% (month 18) were detected due to admissions for diarrheal crises.Finally, PN was suspended due to multiple complications after 22 months.Abstract 4CPS-062 Figure 1Conclusion and RelevanceIn our case, the percentage of TPN volume reduction is higher compared to other studies collected in a recent meta-analysis.1 Moreover, the TPN was totally withdrawn in less time than described in some studies.References and/or Acknowledgements1. Bioletto, F., D’Eusebio, C., Merlo, F.D., Aimasso, U., Ossola, M., Pellegrini, M., Ponzo, V., Chiarotto, A., de Francesco, A., Ghigo, E., Bo, S. Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis. Nutrients 2022, 14, 796. https://doi.org/10.3390/nu14040796Conflict of InterestNo conflict of interest</description><subject>Case reports</subject><subject>Conflicts of interest</subject><subject>Pediatrics</subject><subject>Section 4: Clinical pharmacy services</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpFkM1KxDAUhYMoOIzzCELAdcYkTdPGnQzjDwwoqOuSNDe2Q6epaergRtz4oj6JHcaf1T2L75wLH0KnjM4ZS-Q5rKuu0mFDOOUJAV11cyUO0IRTkRGlpDj8y6k8RrO-rw1NkyRXIlET9C4W9w-ESv718bl81c2gY-1brFuLnW8avyVDh73DnQZb6xjqcoyxhjbibR0r3Fc-RGz8Fhrcv7U2-A3gcSAG0HHzh0Www3MzxNrCBS51DzhANzZP0JHTTQ-znztFT1fLx8UNWd1d3y4uV8QwlgmS5RljucxLXSopjQUqLOdpDtI4rnNXgnXMcKMZE8K4UvBUc2kgUUwq4bJkis72u13wLwP0sVj7IbTjy4JninLKGKUjxfaU2az_AUaLneni13SxM13sTBejw2-aKHep</recordid><startdate>20230323</startdate><enddate>20230323</enddate><creator>Gomez Sanchez, MT</creator><creator>Fernandez Gines, FD</creator><creator>Sanchez Rodriguez, B</creator><creator>Gamez Torres, D</creator><creator>Sanchez Valera, M</creator><creator>Moreno Diaz, T</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>K9.</scope></search><sort><creationdate>20230323</creationdate><title>4CPS-062 Evaluation and follow-up of paediatric patient with short bowel syndrome on treatment with teduglutide: case report</title><author>Gomez Sanchez, MT ; Fernandez Gines, FD ; Sanchez Rodriguez, B ; Gamez Torres, D ; Sanchez Valera, M ; Moreno Diaz, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1174-78711868cac966bde04d2258e6bf2a8fcedf1b2ba1144bfc425a26be391694f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Case reports</topic><topic>Conflicts of interest</topic><topic>Pediatrics</topic><topic>Section 4: Clinical pharmacy services</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gomez Sanchez, MT</creatorcontrib><creatorcontrib>Fernandez Gines, FD</creatorcontrib><creatorcontrib>Sanchez Rodriguez, B</creatorcontrib><creatorcontrib>Gamez Torres, D</creatorcontrib><creatorcontrib>Sanchez Valera, M</creatorcontrib><creatorcontrib>Moreno Diaz, T</creatorcontrib><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gomez Sanchez, MT</au><au>Fernandez Gines, FD</au><au>Sanchez Rodriguez, B</au><au>Gamez Torres, D</au><au>Sanchez Valera, M</au><au>Moreno Diaz, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-062 Evaluation and follow-up of paediatric patient with short bowel syndrome on treatment with teduglutide: case report</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><date>2023-03-23</date><risdate>2023</risdate><volume>30</volume><issue>Suppl 1</issue><spage>A44</spage><epage>A45</epage><pages>A44-A45</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and ImportanceShort bowel syndrome (SBS) is an unusual disorder caused by resection of a part of the small bowel. Frequently these patients are dependent on total parenteral nutrition (TPN) because they suffer malnutrition. Long-term TPN is associated with complications such as infections and thrombosis. Teduglutide is a glucagon-like peptide (GLP-2) analogue that increases the proliferation of intestinal mucosal cells causing an increase in the absorption surface area and a reduction in the volume of TPN.Aim and ObjectivesTo evaluate the effectiveness of teduglutide in a PN-dependent paediatric patient with SBS.Material and MethodsA retrospective, observational and descriptive study of the only referenced case was designed to evaluate the effectiveness of treatment with Teduglutide. For this purpose, the reduction of the volume of TPN until its withdrawal was analysed. This withdrawal must be complete to establish the success of treatment with teduglutide. Data were extracted from the clinical database of the Andalusian Health System (Diraya).ResultsThe patient needed a TPN per day. The following figure shows the percentage of volume of TPN varied every two months from the start of treatment in our patient. The volume of TPN was 500 mL when the first dose of teduglutide (0.05 mg/kg/day) was administered. However, the volume decreased by 45.6% (272mL) after 14 months. Subsequently, volume increases of up to 8% (month 18) were detected due to admissions for diarrheal crises.Finally, PN was suspended due to multiple complications after 22 months.Abstract 4CPS-062 Figure 1Conclusion and RelevanceIn our case, the percentage of TPN volume reduction is higher compared to other studies collected in a recent meta-analysis.1 Moreover, the TPN was totally withdrawn in less time than described in some studies.References and/or Acknowledgements1. Bioletto, F., D’Eusebio, C., Merlo, F.D., Aimasso, U., Ossola, M., Pellegrini, M., Ponzo, V., Chiarotto, A., de Francesco, A., Ghigo, E., Bo, S. Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis. Nutrients 2022, 14, 796. https://doi.org/10.3390/nu14040796Conflict of InterestNo conflict of interest</abstract><cop>London</cop><pub>British Medical Journal Publishing Group</pub><doi>10.1136/ejhpharm-2023-eahp.94</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A44-A45 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_proquest_journals_2790201100 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Case reports Conflicts of interest Pediatrics Section 4: Clinical pharmacy services |
title | 4CPS-062 Evaluation and follow-up of paediatric patient with short bowel syndrome on treatment with teduglutide: case report |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A09%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-062%E2%80%85Evaluation%20and%20follow-up%20of%20paediatric%20patient%20with%20short%20bowel%20syndrome%20on%20treatment%20with%20teduglutide:%20case%20report&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Gomez%20Sanchez,%20MT&rft.date=2023-03-23&rft.volume=30&rft.issue=Suppl%201&rft.spage=A44&rft.epage=A45&rft.pages=A44-A45&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2023-eahp.94&rft_dat=%3Cproquest_bmj_j%3E2790201100%3C/proquest_bmj_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2790201100&rft_id=info:pmid/&rfr_iscdi=true |